Orgenesis announced that the Company’s consortium was awarded a EUR 2.0M grant from the Walloon Government in Belgium, titled: “Monitoring with AI of Decentralized ATMP Manufacturing”. The consortium members include: Orgenesis Services Belgium, Universite catholique de Louvain / TRusted AI Labs and DNAlytics. Advanced Therapy Medicinal Products are among the most innovative and promising biomedicines designed to address unmet medical needs, including cell, gene, exosome and phage therapies. On January 17, 2024, the Walloon government launched a partnership, ATMP-Partenariat d’Innovation Technologique, with an EUR 81 million budget over three years, dedicated to ATMPs, in collaboration with BioWin, the health cluster for Wallonia, and the Public Service of Wallonia. The MAIDAM project is focused on developing AI-based approaches for the monitoring and improvement of decentralized manufacturing processes for ATMPs via federated machine and reinforcement learning utilizing cell therapy processing on small and standardized manufacturing units.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ORGS:
- Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing
- Orgenesis Inc Strikes Definitive Deal to Acquire Octomera LLC
- Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
- Orgenesis to acquire 25% stake in Octomera from MM OS Holdings
- Orgenesis Inc. Secures Acquisition of Octomera LLC